PER® New York Lung Cancer Symposium | Conference

Expert Examines Nuances of Switching Therapies in Progressive EGFR-Positive NSCLC

November 9th 2015

Patience is a virtue when it comes to deciding whether to switch therapies for individuals with metastatic non–small cell lung cancer who appear to be progressing on an EGFR-targeting regimen.

Upfront EGFR TKI Questions Remain in NSCLC

November 9th 2015

Multiple options currently exist for patients with EGFR-positive non–small cell lung cancer, with additional therapies on the horizon, making upfront treatment selection an increasingly difficult endeavor.

Dr. Levy on EGFR TKIs in Lung Cancer

November 9th 2015

Benjamin P. Levy, MD, attending physician, Department of Medicine, Mount Sinai Beth Israel and Mount Sinai St. Luke's Roosevelt, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.

Nivolumab Demonstrates Broad Efficacy in NSCLC

November 7th 2015

The latest FDA approval for nivolumab in non–small cell lung cancer means that the drug potentially can be administered to any patient in the second-line setting, regardless of tumor histology or PD-L1 expression level.

Targeting Rare Mutations in NSCLC the Way of the Future

November 7th 2015

Treatment of patients with non–small cell lung cancer should be based on the identification of rare molecular targets such as BRAF, RET, ROS1, and MET versus clinical characteristics.

Checkpoint Inhibitors Show Promise in SCLC, Mesothelioma

November 7th 2015

Immune checkpoint inhibitors have demonstrated encouraging results for patients with small cell lung cancer and mesothelioma, which are two aggressive thoracic malignancies with few options.

Dr. Chandra Belani on Selecting Anti-PD-L1 Agents in Lung Cancer

November 7th 2015

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with anti–PD-1/PD-L1 treatments in lung cancer.

Dr. Renato Martins on the Effects of Nivolumab and Ipilimumab

November 7th 2015

Dr. Renato G. Martins talks about the impact of nivolumab, an anti–PD-1, and ipilimumab, an anti CTLA-4, in the treatment of lung cancer.

Dr. Chachoua on Afatinib for Exon 19 Mutation in Lung Cancer

February 11th 2015

Abraham Chachoua, MD, associate director of cancer services at NYU Langone Medical Center, talks about targeted treatment for mutations in non-small cell lung cancer and adenocarcinoma.

Dr. Herbst Discusses the State of Immunotherapy in Lung Cancer

November 18th 2014

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses the state of immunotherapy in lung cancer.

Immunotherapies Continue to Impress in NSCLC Trials With Several Forecast for Approval

November 10th 2014

Roy S. Herbst, MD, PhD, led some of the first trials of gefitinib, the EGFR inhibitor that helped introduce targeted therapies of this important mutation into the treatment landscape of non–small cell lung cancer.

With Limited Progression, Maintaining TKI Regimen Often Optimal Approach in Lung Cancer

November 10th 2014

How should oncologists respond when initial treatment of EGFR-mutant or ALK-positive lung cancer with a tyrosine kinase inhibitor (TKI) no longer prevents all disease progression?

Lung Cancer Treatment on Brink of New Molecular Era

November 10th 2014

Although testing for EGFR mutations and ALK rearrangements in patients with NSCLC has become widespread, the time has come to translate into clinical practice next-generation sequencing assays that provide exponentially more information about tumor biology.

Dr. Levy Discusses Recent Updates in Immunotherapy for Lung Cancer

November 10th 2014

Benjamin P. Levy, MD, director, Thoracic Medical Oncology, Mount Sinai Beth Israel, associate director, Cancer Clinical Trials Office, Mount Sinai Hospital, Mt. Sinai School of Medicine, discusses new data on immunotherapy for lung cancer.

Dr. Arcila on the Benefits of New Molecular Diagnostic Platforms for the Treatment of Lung Cancer

November 10th 2014

Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses the benefits of new molecular diagnostic platforms for the treatment of lung cancer.

Dr. Lynch Discusses Resistance to EGFR TKIs in Lung Cancer

November 8th 2014

Thomas J. Lynch, MD, from the Yale Cancer Center, explains how resistance occurs when treating lung cancer patients with EGFR TKIs.

PER Conference Features Expert Views on Lung Cancer Advances

November 7th 2014

Lung cancer experts provided insights into recent developments in the treatment of the disease, covering topics ranging from resistance to targeted therapies to immunotherapy agents under study, during the 9th Annual New York Lung Cancer Symposium in New York City.

Dr. Piperdi on the Stimuvax Vaccine in Lung Cancer

November 20th 2013

Bilal Piperdi, MD, from the Albert Einstein College of Medicine, discussed a trial looking at a vaccine in patients with lung cancer at the 8th Annual New York Lung Cancer Symposium®.

Dr. Mark G. Kris on the Future of Lung Cancer

November 19th 2013

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the future of lung cancer treatment at the 8th Annual New York Lung Cancer Symposium®

PD-1 and PD-L1 Inhibitors Expected to 'Change the Landscape' of Lung Cancer Treatment

November 11th 2013

The future of PD-1 and PD-L1 inhibition in non-small cell lung cancer is bright, with ongoing studies suggesting that the strategy will lead to a 'new world' in the treatment of the disease

NEXT PAGE
PREVIOUS PAGE